Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Insurance Actuaries like these kinds of statistics.
compared to placebo, reflecting that for every 1000 patients treated for 5 years with icosapent ethyl versus placebo approximately 159 MACE could be prevented with Vascepa, including prevention of approximately 12 cardiovascular deaths, 42 heart attacks (myocardial infarctions), 14 strokes, 76 coronary revascularizations and 16 episodes of hospitalization for unstable angina. There was also a 28% reduction of total events in the key secondary endpoint of 3-point MACE in the intent-to-treat population consisting of a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke.
AMRN is "In Play" Mon Mar 18 09:07:52 2019
Amarin presents new data from landmark REDUCE-IT cardiovascular outcomes study of Vascepa -- ''data show relative benefits of Vascepa usage grow over time''
The co presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa (icosapent ethyl), the REDUCE-IT study, showing that Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT. These data presented today as a late-breaker presentation at the American College of Cardiology''s (ACC) 68th Annual Scientific Session in New Orleans, LA, and published simultaneously in the Journal of the American College of Cardiology, extend the scope of consistent effects of Vascepa beyond a patient''s first cardiovascular event to all subsequent cardiovascular events, including cardiovascular death.
In the newly reported data, investigators led by the study''s principal investigator, Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical School, Executive Director of Interventional Cardiovascular Programs in the Heart and Vascular Center at Brigham and Women''s Hospital, and the Principal Investigator and Steering Committee Chair for REDUCE-IT, evaluated patients'' total cardiovascular events during the median study follow up of 4.9 years in REDUCE-IT. These analyses were tertiary or exploratory endpoints in REDUCE-IT. Total events included both a patient''s first occurrence of MACE as well as all subsequent occurrences of MACE. Recurrent cardiovascular events are common in people who have already had a heart attack. Various studies have found a recurrence rate of close to 50% for any cardiovascular event or for subsequent coronary revascularization in the year after a heart attack, and up to 75% of patients have a recurrent event within 3 years.
Vascepa reduced total events, first and subsequent events, by 30% compared to placebo, reflecting that for every 1000 patients treated for 5 years with icosapent ethyl versus placebo approximately 159 MACE could be prevented with Vascepa, including prevention of approximately 12 cardiovascular deaths, 42 heart attacks (myocardial infarctions), 14 strokes, 76 coronary revascularizations and 16 episodes of hospitalization for unstable angina. There was also a 28% reduction of total events in the key secondary endpoint of 3-point MACE in the intent-to-treat population consisting of a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke.
This is more like it!
Investor Relations / Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in
REDUCE-IT.
Mar 18, 2019
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied. Data Show Relative Benefits of Vascepa Usage Grow Over TimeAmarin Schedules Webcast Discussion of Presented Data Today, March 18, 2019 at 4:00-5:00 pm CT
J.L. When is this company going start talking about AA/EPA ratios Verses CVD risk? Instead of this kind of nonsense! This is the kind of news release I was not expecting on after weekend a ACC meeting.
Amarin-News
Over a half million shares in the last 3 minutes for the upside. Should set the tone for next weeks action surrounding the ACC meeting.
I think what they discovered or will in Reduce-It Trig levels had little relationship to risk reduction in Reduce-It. But EPA blood plasma levels had a direct relationship.
OT,
Actually when AZN bought Epanova (OMETHRA). There was an additional amount of money owed to Omethra share holders opon sales of Epanova. Not sure if AZN is still bound to this figure even though it is not being marketed because of Amarin law suit.
AstraZeneca said on Tuesday it had entered into a definitive agreement to buy Omthera for $12.70 per share, or approximately $323 million, a premium of 88 percent to Omthera’s closing price on Friday.
In addition, Omthera shareholders will get “contingent value rights” (CVRs) of up to approximately $4.70 per share, or $120 million in total, depending on the success of Omthera’s experimental drug Epanova, for treating patients with very high triglycerides, a type of blood fat that is bad for the heart.
Yes then we can watch the nay sayer's eat crow. AF and M.H. have a lipid expert, not realizing lipids are a side show. It's about EPA/AA ratios, EPA blood serum content.
Where is Pyre and his DHA hype?
I would be in shock if it makes $21 by closing. I think next week could be a nice run for our stock.
I wish them luck even opon good results. AZN will have to notify Amarin when they resume marketing. Then it's back to court with AZN and their drug EPANOVA violating our patents.
I have a hunch they probably will report mediocre results. These 'Add-in with Statin therapy' lower LDL-C more trials, typically end poorly.
It may be premature to run a trial of a combodrug until it is known that bempedoic acid reduces CVD risk. Esperion was directed by the FDA to run a CVOT some time ago, is it underway?
Ok... that interesting!
That's correct it only applies to buying back the same sock before settlement. You may see the warning when purchasing another stock but you will not be penalized!
it is, it includes today's price action.
Exactly what is happening. We have seen it time and time again over the years with this stock. It'd easy prey.
Actually looks like a two prong problem/failure. The Autopilot systems has been reported to have the same problem 737 Max 8 forcing the nose down. Pilots can switch this off. Not clear if the anti-stall can be disabled or if this was the problem with the crash in Africa have to wait for blackbox analysis.
Maybe no BO offer taken, this weeks and next weeks options selling off!
I was going to mention this, agree when I seen these numbers the other day seemed questionable!
More like the marketeers like to frack with the options players. There the only thing in-play regarding AMRN,
I'm not sure why you are complaining, the costs end up in your lap either way. When Hopital's take in uninsured patients, the state has to fund the hospitals via taxes. In a decent society you have to share the wealth. Take countries where the wealth is isolated, look at Venezuela and other countries that end up in chaos.
I love having these insured patients out there. Think about it, a lot of them may be Vascepa customers in the near future.
That's akin to saying Social Security is socialism. We pay for anything the government does, in the form of taxes or social security deductions.
So the government distributing a vaccine would have been payed for by the tax payers. Now the decision speaks for itself.
That's the way my BC/BS was going back 5 years ago. No questions asked 'Off label script'
I know one thing, good idea to keep our PCP's knowledge ahead of the curve.
Yes probably very small - Light MO is not absorbed by the small intestine and the intestine total area is equivalent to the surface area of a tennis court. So a half of a teaspoon, twice a day had little or no effect on absorption.
I had to do the same thing and return to his office with Jelis trial and a couple of other articles to get my script. I want to visit him the trial results soon and show him the results soon.
If you have been following the science over the years, Reduce-It is not the only study showing exceptional results when using EPA in the cardiac space. Zum use to provide a hyperlink to many EPA trials embedded in a document over the last few years and I don't believe any had negative results.
The so called expert's out there have little knowledge regarding treatment using EPA.
I don't think it would make sense to use the control arm treatment results for this equation.
Actually Johnson Controls is Industrial. They manufacture industrial control systems, I had done some consulting work and custom circuit board design for them up in Minneapolis. They also invited me to San Francisco on a consulting job, so a mini vacation. One reason they brought me was because I was working in the SF area back in the 80's so I was their guide and I helped them when needed on a bid for a electronic prison control system.
From some of the patient reviews I had a chance to read. They seem to think so too.
I think with these newer EMR and (RWE)Real World Evidence data collection systems will help a lot in this area. Sorting out what medicines and surgical techniques actually work well and what does not. This should help reduce hospital stays and reduce cost significantly. I believe that Vascepa may become one of the best preventative medicine's on the market. So the insurance industry/hospitals over government will probably be the key drivers to reducing health care costs. The key being technology. Analytical systems are becoming very popular in the insurance industry.
He sounds like a low life, he seems a little old to be posting propaganda on Youtube.
I didn't clarify that post very well, I am making contributions to a Roth IRA and also have the rollover IRA which I moved the 401K. It was a busy day and I rattled off a few post's pretty quickly. I did make a taxed contribution to the Roll over IRA, but needed to do that to insurance the account remained open until a check was cut from my 401K and mailed to ETRADE. For some reason they do not perform this operation electronically.
The rollover IRA gets taxed at whatever your income rate happens to be when you make a withdraw from the account. So yes in a sense you could be taxed double from the looks of it.
Great video - like they say a picture is worth a thousand words.
Considering the market has been doing badly for two day now, AMRN seems to be holding pretty well. My other stocks are down quite a bit.
He should lose his medical license for rambling like an idiot.